Credit Suisse analyst Geoffrey Weiner initiated coverage of Exelixis with an Outperform rating and $29 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL:
- William Blair says Exelixis cabozantinib patent verdict in line with expectation
- Court Rulings Bring Good and Bad News for Exelixis (NASDAQ:EXEL)
- Exelixis receives favorable ruling in patent litigation with MSN Laboratories
- Exelixis, Ajinomoto enter license agreement
- Exelixis price target lowered to $20 from $21 at Cowen
